Opus Genetics (IRD) analyst forecast and price target
Analyst forecast
Consensus of 18 analyst ratings
Based on 7 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Jones Trading | Maintained | Buy | $17.00 from $10.00 | Oct 6, 2026 |
| Chardan Capital | Maintained | Buy | $16.00 | Oct 2, 2026 |
| Wedbush | Maintained | Outperform | $13.00 from $10.00 | Sep 10, 2026 |
| BTIG | Maintained | Buy | $12.00 | Sep 9, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $8.00 | Sep 9, 2026 |
| Oppenheimer | Maintained | Outperform | $20.00 from $10.00 | Sep 9, 2026 |
| Chardan Capital | Maintained | Buy | $16.00 from $13.00 | Sep 9, 2026 |
| RBC Capital | Maintained | Outperform | $9.00 from $10.00 | Aug 7, 2026 |
| TD Cowen | Initiated Coverage | Buy | — | Jul 29, 2026 |
| BTIG | Maintained | Buy | $12.00 | Jul 6, 2026 |
| Chardan Capital | Maintained | Buy | $13.00 | Jul 6, 2026 |
| Chardan Capital | Maintained | Buy | $13.00 from $11.00 | Jun 18, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $8.00 | Jun 17, 2026 |
| BTIG | Maintained | Buy | $12.00 | Jun 16, 2026 |
| Citizens | Maintained | Market Outperform | $11.00 | Jun 15, 2026 |
| Guggenheim | Initiated Coverage | Buy | $16.00 | Jun 4, 2026 |
| Leerink Partners | Initiated Coverage | Outperform | $10.00 | May 21, 2026 |
| Citizens | Maintained | Market Outperform | $11.00 from $12.00 | May 13, 2026 |
| Citizens | Initiated Coverage | Market Outperform | $12.00 | Apr 28, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | $15.00 | Mar 30, 2026 |
Frequently asked questions
What is the price target for IRD stock?
The average 12-month analyst price target for Opus Genetics (IRD) is $13.57, with a high estimate of $20.00 and a low of $8.00, across 7 analysts.
Is IRD a buy, sell, or hold?
Analysts covering Opus Genetics currently average a Buy rating: 18 buy, 0 hold and 0 sell, from 18 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for IRD?
The average price target of $13.57 implies 220.08% upside from the last price of $4.24.
What is the latest analyst rating on IRD?
On Oct 6, 2026, Jones Trading maintained Opus Genetics at Buy with a price target of $17.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.